1 week 16
Extreme 16
29.15
1 month 16
Extreme 16
29.15
Current year 16
Extreme 16
29.15
1 year 16
Extreme 16
29.15
3 years 16
Extreme 16
29.15
5 years 16
Extreme 16
29.15
10 years 16
Extreme 16
29.15
Manager TitleAgeSince
Corporate Officer/Principal 42 2018-05-31
Chief Executive Officer 50 2026-06-01
Chief Tech/Sci/R&D Officer - 2021-03-03
Director TitleAgeSince
Chairman 73 2017-12-31
Director/Board Member 77 2017-05-31
Director/Board Member 46 2022-12-31
Date Insider Type Main position Quantity % Market Cap.
7/30/26 Other

Chairman

169,468 0.6096%
7/30/26 Other

Chairperson

694,150 2.4969%
7/30/26 Other

Director

96,367 0.3466%
Change 5-day change 1-year change 3-year change Capi.($)
+56.25%-.--% - - 996M
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+411.96%+495.33% 39.87B
-1.16%+12.96%+28.81%+7.25% 38.68B
-1.88%-3.03%+5.69%+53.00% 35.13B
-1.74%+5.12%+14.44%+41.77% 29.79B
-0.21%-4.04%+36.40%+125.75% 16.11B
-2.85%-3.92% - - 16.08B
-0.64%+2.65%+3.40%+13.11% 13.61B
-1.19%-1.32%-1.73%-34.37% 12.62B
Average +4.28%+0.95%+62.16%+89.14% 25.14B
Weighted average by Cap. -1.37%+2.03%+79.78%+108.61%

Financials

2024 2025
Net sales 8.01M 6.96M 6.48M 5.95M 11.24M 765M 11.41M 76.41M 29.99M 381M 30.09M 29.43M 1.28B 38.47M 33.44M 31.12M 28.58M 53.96M 3.67B 54.8M 367M 144M 1.83B 144M 141M 6.13B
Net income -111M -96.76M -90.06M -82.69M -156M -10.63B -159M -1.06B -417M -5.29B -418M -409M -17.74B -128M -111M -104M -95.23M -180M -12.24B -183M -1.22B -480M -6.09B -481M -471M -20.43B
Net Debt - -
Logo Apnimed, Inc.
Apnimed, Inc. is a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. The Company's clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA). Oxnimbi is designed to target the neuromuscular defect of OSA by improving upper airway muscle activity to help maintain airway patency and prevent airway collapse during sleep.
Employees
65
Date Price Change Volume
26-07-31 US$25.00 +56.25% 3,444,667
26-07-30 US$16.00 -.--% 0
  1. Stock Market
  2. Stocks
  3. APMD Stock